Neonatal Candida meningitis.
Candida: spp. are becoming one of the most common pathogens associated with sepsis in the setting of neonatal intensive care. Invasive therapies aimed at improving patient survival, particularly among premature infants, contribute significantly to this alteration in the distribution of neonatal pathogens. Prematurity is one of the principle risk factors associated with the development of neonatal meningitis in this patient population. Untreated, neonatal candidal meningitis is associated with a poor outcome both in terms of morbidity and mortality. However, early diagnosis with timely initiation of antifungal therapy will improve outcome significantly. The following review outlines the pathogenesis, clinical features, diagnosis, and current treatment options for neonatal candidal meningitis.
Moylett
Edina H
EH
Section of Allergy and Immunology and the Section of Pediatric Infectious Diseases, Baylor College of Medicine and the Allergy and Immunology Service, Texas Children's Hospital, Houston, TX 77030, USA. emoylett@bcm.tmc.edu
D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D016921:Meningitis, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D012307:Risk Factors; D016896:Treatment Outcome
D000935:Antifungal Agents